Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

J0174 Injection, lecanemab-irmb, 1 milligrams

J Codes (Drugs)

Also known as: lecanemab, Leqembi

Lecanemab-irmb injection 1 milligram, a monoclonal antibody against amyloid-beta for early Alzheimer's disease.

In Plain Language

Alzheimer's disease treatment; memory loss medication

Clinical Context

Intravenous monoclonal antibody targeting amyloid-beta for early symptomatic Alzheimer's disease and mild cognitive impairment. Slows cognitive decline. Requires amyloid positron emission tomography or cerebrospinal fluid biomarker confirmation.

RVU Information

CPT J0174 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.

Billing & Documentation

J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.

Specialties

NeurologyGeriatricsInternal Medicine

Frequently Asked Questions

What is CPT code J0174?

CPT J0174 (Injection, lecanemab-irmb, 1 milligrams) is a J Codes (Drugs) code. Lecanemab-irmb injection 1 milligram, a monoclonal antibody against amyloid-beta for early Alzheimer's disease.

How is J0174 administered?

CPT J0174 is administered by a healthcare provider, typically via injection or infusion. Intravenous monoclonal antibody targeting amyloid-beta for early symptomatic Alzheimer's disease and mild cognitive impairment. Slows cognitive decline. Requires amyloid positron emission tomography or cerebrospinal fluid biomarker confirmation. It is used by Neurology, Geriatrics, Internal Medicine.

When is CPT J0174 used?

Intravenous monoclonal antibody targeting amyloid-beta for early symptomatic Alzheimer's disease and mild cognitive impairment. Slows cognitive decline. Requires amyloid positron emission tomography or cerebrospinal fluid biomarker confirmation.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.